Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients

BACKGROUND: There is increasing evidence that immunotherapy with nivolumab, an anti‐programmed death 1 monoclonal antibody, is effective in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the predictive role of hematological inflammatory ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuki, Takashi, Okamoto, Isaku, Fushimi, Chihiro, Sawabe, Michi, Kawakita, Daisuke, Sato, Hiroki, Tsukahara, Kiyoaki, Kondo, Takahito, Okada, Takuro, Tada, Yuichiro, Miura, Kouki, Omura, Go, Yamashita, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367642/
https://www.ncbi.nlm.nih.gov/pubmed/32441463
http://dx.doi.org/10.1002/cam4.3124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367642/
https://www.ncbi.nlm.nih.gov/pubmed/32441463
http://dx.doi.org/10.1002/cam4.3124

Ejemplares similares